Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAGLA | Q9Y4D2 | 10/20 | 1.00 |
| ▸ | DAGLB | Q8NCG7 | 7/20 | 0.85 |
| ▸ | DDHD2 | O94830 | 1/20 | 0.66 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.39 |
| ▸ | GCGR | P47871 | 2/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.37 |
| ▸ | LIPE | Q05469 | 1/20 | 0.37 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.37 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.36 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18935831 | 0.92 | DAGLA (1.00) | DAGLADAGLBDDHD2GCGRGRIN2B | |
| SCHEMBL18935832 | 0.91 | DAGLA (1.00) | DAGLADAGLBDDHD2 | |
| SCHEMBL18935851 | 0.86 | DAGLA (1.00) | DAGLADAGLBDDHD2SERPINE1GCGR | |
| SCHEMBL18935850 | 0.85 | DAGLA (1.00) | DAGLADAGLBDDHD2SERPINE1GCGR | |
| SCHEMBL20576782 | 0.81 | DAGLA (0.69) | DAGLADAGLBDDHD2SERPINE1GCGR | |
| SCHEMBL18935859 | 0.81 | DAGLA (1.00) | DAGLADAGLBDDHD2SERPINE1GCGR | |
| SCHEMBL18935828 | 0.81 | DAGLA (1.00) | DAGLADAGLBDDHD2SERPINE1GCGR | |
| SCHEMBL29659427 | 0.79 | DDHD2 (1.00) | DAGLADAGLBDDHD2SERPINE1GCGR | |
| SCHEMBL18921268 | 0.79 | DAGLB (1.00) | DAGLADAGLBDDHD2GCGRGRIN2B | |
| SCHEMBL18935782 | 0.78 | DAGLA (1.00) | DAGLADAGLBDDHD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10583137-B2 | Triazole DAGLα inhibitors | THE SCRIPPS RESEARCH INSTITUTE (US) | 2020-03-10 | — | — | US | disclosed |
| US-20180344729-A1 | TRIAZOLE DAGLAlpha INHIBITORS | THE SCRIPPS RESEARCH INSTITUTE | 2018-12-06 | — | — | US | disclosed |
| WO-2017096315-A1 | TRIAZOLE DAGL(α) INHIBITORS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2017-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10583137-B2 | Triazole DAGLα inhibitors | DAGLB, DAGLA, DGKB | DAGLA 2/4885DAGLB 1/4885DDHD2 2253/4885 |
| US-20180344729-A1 | TRIAZOLE DAGLAlpha INHIBITORS | DAGLB, DAGLA, DGKB | DAGLA 2/4885DAGLB 1/4885DDHD2 1590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.